256 related articles for article (PubMed ID: 36566797)
1. Overcoming intrinsic resistance in gram-negative bacteria using small molecule adjuvants.
Melander RJ; Mattingly AE; Nemeth AM; Melander C
Bioorg Med Chem Lett; 2023 Jan; 80():129113. PubMed ID: 36566797
[TBL] [Abstract][Full Text] [Related]
2. Synergy between Active Efflux and Outer Membrane Diffusion Defines Rules of Antibiotic Permeation into Gram-Negative Bacteria.
Krishnamoorthy G; Leus IV; Weeks JW; Wolloscheck D; Rybenkov VV; Zgurskaya HI
mBio; 2017 Oct; 8(5):. PubMed ID: 29089426
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
Domalaon R; Idowu T; Zhanel GG; Schweizer F
Clin Microbiol Rev; 2018 Apr; 31(2):. PubMed ID: 29540434
[TBL] [Abstract][Full Text] [Related]
4. RND efflux pumps in Gram-negative bacteria; regulation, structure and role in antibiotic resistance.
Colclough AL; Alav I; Whittle EE; Pugh HL; Darby EM; Legood SW; McNeil HE; Blair JM
Future Microbiol; 2020 Jan; 15():143-157. PubMed ID: 32073314
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic adjuvants: an alternative approach to overcome multi-drug resistant Gram-negative bacteria.
Liu Y; Li R; Xiao X; Wang Z
Crit Rev Microbiol; 2019 May; 45(3):301-314. PubMed ID: 30985240
[TBL] [Abstract][Full Text] [Related]
6. Measuring the activity of active efflux in gram-negative bacteria.
Webber MA; Coldham NG
Methods Mol Biol; 2010; 642():173-80. PubMed ID: 20401594
[TBL] [Abstract][Full Text] [Related]
7. Nonlethal Molecular Nanomachines Potentiate Antibiotic Activity Against Gram-Negative Bacteria by Increasing Cell Permeability and Attenuating Efflux.
Santos AL; Liu D; van Venrooy A; Beckham JL; Oliver A; Tegos GP; Tour JM
ACS Nano; 2024 Jan; 18(4):3023-3042. PubMed ID: 38241477
[TBL] [Abstract][Full Text] [Related]
8. Restoring and Enhancing the Potency of Existing Antibiotics against Drug-Resistant Gram-Negative Bacteria through the Development of Potent Small-Molecule Adjuvants.
Yu B; Roy Choudhury M; Yang X; Benoit SL; Womack E; Van Mouwerik Lyles K; Acharya A; Kumar A; Yang C; Pavlova A; Zhu M; Yuan Z; Gumbart JC; Boykin DW; Maier RJ; Eichenbaum Z; Wang B
ACS Infect Dis; 2022 Aug; 8(8):1491-1508. PubMed ID: 35801980
[TBL] [Abstract][Full Text] [Related]
9. The development of efflux pump inhibitors to treat Gram-negative infections.
Blanco P; Sanz-García F; Hernando-Amado S; Martínez JL; Alcalde-Rico M
Expert Opin Drug Discov; 2018 Oct; 13(10):919-931. PubMed ID: 30198793
[TBL] [Abstract][Full Text] [Related]
10. Multidrug Efflux Pumps and the Two-Faced Janus of Substrates and Inhibitors.
Zgurskaya HI; Walker JK; Parks JM; Rybenkov VV
Acc Chem Res; 2021 Feb; 54(4):930-939. PubMed ID: 33539084
[TBL] [Abstract][Full Text] [Related]
11. Staphylococcal Bacterial Persister Cells, Biofilms, and Intracellular Infection Are Disrupted by JD1, a Membrane-Damaging Small Molecule.
Dombach JL; Quintana JLJ; Detweiler CS
mBio; 2021 Oct; 12(5):e0180121. PubMed ID: 34634935
[TBL] [Abstract][Full Text] [Related]
12. A forward chemical screen identifies antibiotic adjuvants in Escherichia coli.
Taylor PL; Rossi L; De Pascale G; Wright GD
ACS Chem Biol; 2012 Sep; 7(9):1547-55. PubMed ID: 22698393
[TBL] [Abstract][Full Text] [Related]
13. Baicalein Resensitizes Multidrug-Resistant Gram-Negative Pathogens to Doxycycline.
Wang Y; Su J; Zhou Z; Yang J; Liu W; Zhang Y; Zhang P; Guo T; Li G
Microbiol Spectr; 2023 Jun; 11(3):e0470222. PubMed ID: 37070985
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of the over-expression of efflux pump in nonfermentative Gram-negative bacilli, development of efflux pump inhibitors.
Vila J; Martínez JL
Curr Drug Targets; 2008 Sep; 9(9):797-807. PubMed ID: 18781925
[TBL] [Abstract][Full Text] [Related]
15. A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
Yang X; Goswami S; Gorityala BK; Domalaon R; Lyu Y; Kumar A; Zhanel GG; Schweizer F
J Med Chem; 2017 May; 60(9):3913-3932. PubMed ID: 28399372
[TBL] [Abstract][Full Text] [Related]
16. An Original and Efficient Antibiotic Adjuvant Strategy to Enhance the Activity of Macrolide Antibiotics against Gram-Negative Resistant Strains.
Troudi A; Bolla JM; Klibi N; Brunel JM
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293314
[TBL] [Abstract][Full Text] [Related]
17. New understanding of multidrug efflux and permeation in antibiotic resistance, persistence, and heteroresistance.
Manrique PD; López CA; Gnanakaran S; Rybenkov VV; Zgurskaya HI
Ann N Y Acad Sci; 2023 Jan; 1519(1):46-62. PubMed ID: 36344198
[TBL] [Abstract][Full Text] [Related]
18. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery.
Schweizer HP
Expert Opin Drug Discov; 2012 Jul; 7(7):633-42. PubMed ID: 22607346
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic adjuvants: synergistic tool to combat multi-drug resistant pathogens.
Kumar V; Yasmeen N; Pandey A; Ahmad Chaudhary A; Alawam AS; Ahmad Rudayni H; Islam A; Lakhawat SS; Sharma PK; Shahid M
Front Cell Infect Microbiol; 2023; 13():1293633. PubMed ID: 38179424
[TBL] [Abstract][Full Text] [Related]
20. New potentiators of ineffective antibiotics: Targeting the Gram-negative outer membrane to overcome intrinsic resistance.
Klobucar K; Brown ED
Curr Opin Chem Biol; 2022 Feb; 66():102099. PubMed ID: 34808425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
